Clinical-stage biopharmaceutical company seeking to transform he treatment of mental health conditions Atai Life Sciences (ATAI) announced having launched Revixia Life Sciences, as its wholly owned subsidiary.
Revixia will be engaging in developing Salvinorin A (SalA) to treat various mental health disorders. Salvinorin A is a word derived from Salvia divinorum, which is a unique non-nitrogenous agonist of the kappa-oppiod receptor (KOR) with potential use in treatment-resistant depression (TRD), substance use disorder (SUD) and pain.
Since time immemorial, Salvia divinorum has been used by the Mazatec people in Oaxaca, Mexico to treat a variety of illnesses including rheumatism, headaches and diarrhea.
“Due to SalA’s short psychedelic effect, it will be an attractive option for those who would like psychedelic treatment but are unwilling or unable to participate in longer sessions. The shorter experience will allow for more practical administration and monitoring, which may even make it possible to attend psychotherapy sessions on the same day,” said Revixia’s CEO, Glenn Short.
